Tom 7, Nr 4 (2022)
Artykuł przeglądowy
Opublikowany online: 2022-08-23

dostęp otwarty

Wyświetlenia strony 3506
Wyświetlenia/pobrania artykułu 88
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Tumor and normal tissue radiation side effects

Bogusław Maciejewski1
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(4):281-285.

Streszczenie

This paper presents the various side effects of radiation including tumor cure probability (TCP) accompanied with fre­quently severe but transient acute side effects in the surrounding normal (mainly epithelial) tissues and also the risk of late side effects in normal organs, confined to their partial or whole volumes. Besides the local side effects, unexpected exposure to low radiation doses results in the stochastic risk of mutagenic, teratogenic or cancerogenic side effects. In order to minimize the risk of various radiation side effects, some obligatory radiation protection constraints should be restrictively fulfilled.

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. McBride WH, Withers HR, Schaue D. Biological basis of radiation therapy. In: Perez CA, Brandy LW. ed. Principles and Practice of Radiation Oncology. VII ed. Wolters-Kluwer, Philadelphia 2018: 87–111.
  2. Fletcher GH. Textbook of Radiotherapy. I, II and III eds. Lea and Febiger, Philadelphia 1966, 1973, 1980.
  3. Maciejewski B, Miszczyk L, Tarnawski R, et al. How the game is played--challenge between therapeutic benefit and acute toxicity in fractionated radiotherapy. Front Radiat Ther Oncol. 2002; 37: 174–184.
  4. Maciejewski B, Suwiński R, Withers HR, et al. To boost or not to boost in radiotherapy. Nowotwory J Oncol. 2004; 54(5): 446–458.
  5. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988; 27(2): 131–146.
  6. Maciejewski B, Withers HR, Taylor JM, et al. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx. Part 2. Normal tissue responses: acute and late effects. Int J Radiat Oncol Biol Phys. 1990; 18(1): 101–111.
  7. Maciejewski B, Blamek S, Składowski K, et al. Radiobiological rationale for stereotactic hypofractionated radiosurgery Part II. Normal tissue tolerance — dose constraints. Nowotwory. Journal of Oncology. 2018; 68(2): 79–86.
  8. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008; 18(4): 215–222.
  9. Rubin P, Constine LS, Williams JP. Late effect of cancer treatment. In: Perez CA, Brady Lw. ed. Principles and Practice of Radiation Oncology. Lippincott-Raven Publ, Philadelphia 1998: 155–212.
  10. Rubin P. Clinical Oncology. A Multidisciplinary Approach. WB Saunders, Philadelphia 1993.
  11. Maciejewski B, Suwiński R, Blamek S. Radiobiologia kliniczna w radioonkologii. Med Prak, Kraków 2019: 25–124.
  12. Kaanders J, Kogel Av, Ang KK. Altered fractionation: limited by mucosal reactions? Radiotherapy and Oncology. 1999; 50(3): 247–260.
  13. Denham J, Walker Q, Lamb D, et al. Mucosal regeneration during radiotherapy. Radiotherapy and Oncology. 1996; 41(2): 109–118.
  14. Denham JW, Hamilton CS, Simpson SA, et al. Acute reaction parameters for human oropharyngeal mucosa. Radiotherapy and Oncology. 1995; 35(2): 129–137.
  15. Maciejewski B, Miszczyk L, Składowski K. Which normal tissue reactions could be considered as dose limiting for altered radiotherapy in head and neck cancer? Medimond Inc 2022: 714–730.
  16. ICRP Publication 60. Documentations of the International Commission on Radiobiological Protection. Pergamon Press, Oxford, New York 1991.